Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Font Size

Genetics of Prostate Cancer (PDQ®): Genetics - Health Professional Information [NCI] - Genes With Potential Clinical Relevance in Prostate Cancer Risk

Table 10. Case Series ofBRCA1andBRCA2and Prostate Cancer Risk continued...

These case series confirm that mutations in BRCA1 and BRCA2 do not play a significant role in hereditary prostate cancer. However, germline mutations in BRCA2 account for some cases of early-onset prostate cancer, although this is estimated to be less than 1% of early-onset prostate cancers in the United States.[21]

Prostate cancer aggressiveness inBRCAmutation carriers

The studies summarized in Table 11 used similar case-control methods to examine features of prostate cancer aggressiveness among men with prostate cancer found to harbor a BRCA1/BRCA2 mutation.

Table 11. Case-Control Studies ofBRCA1andBRCA2and Prostate Cancer Aggressiveness

Study Population Controls Gleason Scorea PSA a Tumor Stage or Gradea Comments
AJ = Ashkenazi Jewish; CI = confidence interval; HR = hazard ratio; OR = odds ratio; PSA = prostate-specific antigen.
a Measures of prostate cancer aggressiveness.
Tryggvadóttir et al. (2007)[23] 30 men diagnosed with prostate cancer who wereBRCA2999del5 founder mutation carriers 59 men with prostate cancer matched by birth and diagnosis year and confirmed not to carry theBRCA2999del5 mutation Gleason score 7-10: Not assessed Stage IV at diagnosis:
- Cases: 84% - Cases: 55.2%
- Controls: 52.7% - Controls: 24.6%
Agalliu et al. (2009)[15] 979 AJ men diagnosed with prostate cancer between 1978 and 2005 (mean and median year of diagnosis: 1996) 1,251 AJ men with no history of cancer Gleason score 7-10: Not assessed Not assessed
-BRCA1185delAG mutation: OR, 3.54 (95% CI, 1.22-10.31)
-BRCA26174delT mutation: OR, 3.18 (95% CI, 1.37-7.34)
Edwards et al. (2010)[26] 21 men diagnosed with prostate cancer who harbored aBRCA2 mutation: 6 with early-onset disease (≤55 y) from a UK prostate cancer study and 15 unselected for age at diagnosis from a UK clinical series 1,587 age- and stage-matched men with prostate cancer Not assessed PSA ≥25 ng/mL: HR, 1.39 (95% CI, 1.04-1.86) Stage T3: HR, 1.19 (95% CI, 0.68-2.05)
Stage T4: HR, 1.87 (95% CI, 1.00-3.48)
Grade 2: HR, 2.24 (95% CI, 1.03-4.88)
Grade 3: HR, 3.94 (95% CI, 1.78-8.73)
Gallagher et al. (2010)[16] 832 AJ men diagnosed with localized prostate cancer between 1988 and 2007, of which there were sixBRCA1mutation carriers and 20BRCA2mutation carriers 454 AJ men with no history of cancer Gleason score 7-10: Not assessed Not assessed TheBRCA15382insC founder mutation was not tested in this series.
BRCA26174delT mutation: HR, 2.63 (95% CI, 1.23-5.6;P = .001)
Thorne et al. (2011)[27] 40 men diagnosed with prostate cancer who were BRCA2 mutation carriers from 30 familial breast cancer families from Australia and New Zealand 97 men from 89 familial breast cancer families from Australia and New Zealand with prostate cancer and noBRCAmutation found in the family Gleason score ≥8: PSA 10-100 ng/mL: Stage ≥pT3 at presentation: BRCA2mutation carriers were more likely to have high-risk disease byD'Amico criteriathan were noncarriers (77.5% vs. 58.7%,P = .05).
-BRCA2mutations: 35% (14/40) -BRCA2mutations: 44.7% (17/38)
-BRCA2mutations: 65.8% (25/38) - Controls: 27.9% (27/97)
PSA >101 ng/mL:
- Controls: 33.0% (25/97) -BRCA2mutations: 10% (4/40) - Controls: 22.6% (21/97)
-Controls: 2.1% (2/97)
Castro et al. (2013)[28] 2,019 men diagnosed with prostate cancer from the United Kingdom, of whom 18 wereBRCA1mutation carriers and 61 wereBRCA2mutation carriers 1,940 men who wereBRCA1/2noncarriers Gleason score >8: BRCA1median PSA: 8.9 (range, 0.7-3,000) Stage ≥pT3 at presentation: Nodal metastasis and distant metastasis were higher in men with aBRCAmutation than in controls.
-BRCA1mutations: 27.8% (5/18) -BRCA1: 38.9% (7/18)
-BRCA2mutations: 37.7% (23/61) BRCA2 median PSA: 15.1 (range, 0.5-761) -BRCA2 : 49.2% (30/61)
- Controls 15.4% (299/1,940) Controls median PSA: 11.3 (range, 0.2-7,800) - Controls: 31.7% (616/1,940)
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12
Next Article:

Today on WebMD

man with doctor
Symptoms, risks, treatments
man coughing
Men shouldn’t ignore
prostate cancer cells
What does this diagnosis mean?
doctor and male patient
Is it worth it?
cancer fighting foods
15 Cancer Symptoms Men Ignore
Prostate Enlarged
Picture Of The Prostate
Prostate Cancer Quiz
screening tests for men
Prostate Cancer Symptoms
Vitamin D